Chapter 64: Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

In the early 2000s,

global prescriptions for hormone therapy just dropped by like 80 percent almost overnight.

Yeah.

It was massive.

Women panicked, providers panicked, and clinical practices completely shifted.

Right.

But the crazy part is, years later, the medical community realized that the study that caused all this fear was, well, fundamentally misunderstood.

Totally misunderstood.

And that is exactly why we need to dig into this stuff.

Exactly.

So welcome to the Deep Dive.

Today, we are taking you through the basic pharmacology and non -contraceptive applications of estrogens and progestins.

And we're pulling this directly from Chapter 64 of Landon's Pharmacology for Nursing Care.

Right.

And the mission here is to get you, the nursing student, fully prepared.

We want you to understand the actual mechanisms behind these medications.

So that when you're on the floor, you know, the patient teaching and the safety alerts aren't just, well, just memorized facts.

They're logical clinical decisions.

Right.

Because we're going to focus purely on the text today.

We really want to unpack the why and the how at like both the cellular and systemic level.

Because understanding that biological mechanism is what actually bridges the gap between, you know, just reading a textbook and keeping a patient safe in a real clinical setting.

So let's start with the baseline, right?

Before we can understand how manufactured hormones act as medications, we kind of need to understand the endogenous hormones they're mimicking.

Yeah.

You have to know what the body does naturally first.

So the text begins by mapping out the 28 -day menstrual cycle.

Which is driven by this highly coordinated feedback loop, right?

Exactly.

The cycle is essentially divided into two halves and it's governed by hormones from the anterior pituitary gland.

Okay.

So the first half.

Right.

The first half, days 1 through 14, is the follicular phase.

The pituitary secretes follicle stimulating hormone or FSH.

Which I mean, the name kind of gives it away.

It really does.

It travels to the ovaries and stimulates several ovarian follicles to ripen.

And as those mature, they begin secreting estrogens.

Okay.

And meanwhile, in the uterus, that rising estrogen is causing the endometrium, the inner lining of the uterus, to thicken, right?

Yeah.

It increases in vascularity.

Yeah.

The body is basically preparing a nutrient -rich environment for a potential pregnancy.

I always conceptualize this first half of the cycle by thinking of estrogen as the builder.

Oh, I like that.

The builder.

Yeah.

You know, it shows up at the uterus, just starts constructing this thick, plush environment.

And as the builder works, estrogen levels rise, which eventually signals the pituitary to stop releasing FSH.

And that rising estrogen triggers a really sudden shift.

So right around day 14, mid -cycle, the pituitary releases a massive surge of luteinizing hormone.

The LH surge.

Exactly.

The LH surge.

And that causes one dominant follicle to rapidly swell,

burst, and release an ovum.

Which is ovulation.

Right.

Ovulation.

And that kicks off the second half of the cycle, known as the luteal phase.

But the ruptured follicle doesn't just disappear, right?

It actually changes its entire function.

It does.

It transforms into a structure called the corpus luteum under the influence of that same LH.

And once it's formed, this corpus luteum starts heavily secreting our second major hormone, which is progesterone, along with, you know, some continued estrogen.

Which brings in the second half of my analogy.

So if estrogen is the builder constructing the house, progesterone is like the furniture or the maintainer.

The maintainer, yeah.

Right.

It moves in the furniture, turns on the utilities, and makes the environment actually ready to sustain life.

Physiologically, yeah, that's exactly it.

Progesterone increases the secretory activity of the uterus, maintaining that hypertrophied state.

But if fertilization and implantation don't happen.

Then the corpus luteum has a limited lifespan, it eventually atrophies.

And when it does, the production of both estrogen and progesterone drops sharply.

So the builder and the maintainer both leave the job site.

Basically, yeah.

And without that hormonal support, the thickened endometrium simply cannot sustain itself.

So it breaks down, resulting in menstruation, and the cycle just begins all over again.

Okay, so that's the endogenous baseline.

Let's look at estradiol, which is the major ovarian estrogen driving that first half.

Right.

To understand how we use it as a drug, we have to look at how it works at the cellular level.

Because it's a little different than other drugs, right?

It is.

Unlike a lot of drugs that just bind to receptors on the outside of a cell membrane, estrogens are lipid soluble steroidal hormones.

Meaning they can just pass right through.

Exactly.

They diffuse straight through the cell membrane, migrate all the way into the nucleus, and bind with specific nuclear estrogen receptors, namely, ER alpha and ER beta.

So they're actually altering the rate of gene transcription right at the DNA level.

Yes, exactly.

Now, the text does note that some estrogen receptors are located on the cell surface for rapid responses, but the primary long -lasting action is nuclear.

And because these ER alpha and ER beta receptors are located in tissues all over the body, estrogen's effects go way beyond just the reproductive tract.

Oh, absolutely.

Systemically, it does a lot.

Let's look at those systemic effects, because this is where the nursing implications really start to pile up for you guys.

For example, the text mentions that estrogen promotes epiphyseal closure in bones.

What's the mechanism there?

So during puberty, long bones grow at the epiphyseal plates or the growth plates.

Estrogen actually accelerates the ossification of those plates.

So it turns them to solid bones.

Right.

Once they fully calcify and close, linear bone growth stops.

But then later in life, estrogen plays a different role in the skeletal system.

It blocks bone resorption.

Meaning it stops the breakdown of bone?

Exactly.

It essentially stops the osteoclasts from breaking down bone tissue, which is incredibly vital for maintaining bone mass in adulthood.

OK.

And it also has major effects on the cardiovascular system.

It reduces LDL, the bad cholesterol, and raises HDL, the good cholesterol.

While also promoting vasodilation, yeah.

But OK, I'm a little confused by the blood coagulation data in the text.

It says estrogen promotes clotting factors, but it also increases factors that break down fibrin.

That sounds totally contradictory.

How does a nurse know if their patient on estrogen is going to, like, clot or bleed?

It is a physiological paradox, honestly.

Estrogen is essentially ramping up both the creation of clots and the destruction of clots at the exact same time.

Well, that sounds risky.

It can be.

The net effect on the patient, whether they lean towards thrombosis or bleeding,

often depends on their individual genetics and other compounding risk factors.

Oh, so that's why some patients on estrogen therapies develop dangerous clots, while others do perfectly fine.

Exactly.

And beyond the cardiovascular system, estrogen also provides neuroprotection in the central nervous system, and it promotes glucose uptake by increasing insulin sensitivity.

Wow.

So when we use estrogen therapeutically, we have a really wide variety of applications.

Right.

Things like menopausal hormone therapy, treating female hypogrenatism, controlling severe acne.

Even providing palliation for advanced prostate cancer or off -label use for gender affirmation therapy.

Yes, all of those.

But the textbook includes a massive safety alert regarding unopposed estrogen.

Unopposed estrogen.

What exactly does that mean?

It simply means giving a patient estrogen without any progestin to balance it out.

Okay.

If you give unopposed estrogen to a patient who still has an intact uterus, you significantly increase their risk of endometrial cancer.

Oh, because of the builder analogy?

Yes.

Think back to the mechanism.

Estrogen is the builder.

If you introduce a pharmacological builder that just keeps thickening the uterine lining day after day without the maintainer to control and eventually shed it, you get endometrial hyperplasia.

Just this massive overgrowth of cells.

Exactly.

And over time, that overgrowth can mutate into cancer.

Okay.

That makes the pathology very clear.

What other severe risks are we monitoring for?

Well, estrogen therapies increase the risks for deep vein thrombosis, or DVT, and stroke.

Which ties back to that coagulation paradox we talked about.

Right.

It also increases the risk of dementia in patients 65 and older.

Because of these mechanisms, estrogen is strictly contraindicated in patients with a history of DVT, pulmonary embolism, stroke, or unexplained vaginal bleeding.

And that's contraindicated during pregnancy too, right?

Definitely.

And from an occupational safety standpoint,

NOSH classifies estrogen as a hazardous drug because of the reproductive risks to healthcare workers who handle it.

Good to know.

Now, on a day -to -day basis, the most common side effect the patient will actually complain about is nausea.

Yeah, very common.

But we can reassure them that this usually diminishes with continued use, right?

Usually, yes.

Now, because of these systemic risks, providers are highly selective about how they administer estrogen.

The text details oral, transdermal, intravaginal, and parenteral routes.

Right.

And because oral estrogen has to survive the liver's first -pass metabolism, providers often try to bypass the gastrointestinal tract entirely.

So they use transdermal delivery?

Yeah, through patches, emulsions, sprays, or gels.

It offers several distinct advantages over a simple oral pill.

Like what?

Well, first, because it bypasses that liver first -pass metabolism, the total required dose is greatly reduced.

And a lower dose means less nausea for the patient.

Exactly.

Second, blood levels of the hormone remain much steadier, avoiding those peaks and troughs of daily oral dosing.

Right.

But most importantly, transdermal administration carries a lower risk for DVT, pulmonary embolism, and stroke compared to oral routes.

That's huge.

Now, given the severe risks associated with systemic estrogen, we also see drugs classified as serums.

Selective estrogen receptor modulators.

Right, like tamoxifen and roloxafen.

How are these altering the mechanism?

The goal of a serm is to selectively activate estrogen receptors in some tissues to get the benefits, while blocking them in other tissues to avoid the drawbacks.

Okay, so give me an example.

Take tamoxifen.

It blocks estrogen receptors in the breast, making it an effective treatment for estrogen receptor -positive breast cancer.

That's amazing.

But at the same time, it activates estrogen receptors in the bone, helping protect against osteoporosis.

Okay, but because it's activating receptors in other tissues, it's probably not a perfect solution.

No, it's not.

Tamoxifen still carries risks for endometrial cancer and thromboembolism.

What about roloxafen?

Roloxafen works similarly, but it does not activate endometrial receptors, so it avoids that specific uterine cancer risk.

Got it.

So the selectivity is tissue -dependent, which means your nursing monitoring also has to

Exactly.

And inevitably,

given these black box warnings about synthetic hormones and serums, you're going to have patients who ask about natural alternatives.

Oh, always.

Specifically phytoestrogens, like soy isoflavones.

Right.

Do those plant -based compounds actually work?

Well, phytoestrogens are weak plant -based compounds that have a similar chemical structure to estrogen.

Many patients self -treat with them for menopausal symptoms.

But what does the data say?

The textbook notes that data from randomized controlled trials are highly inconsistent.

They aren't heavily recommended as a clinical substitute, but they aren't completely discouraged either.

So it's kind of a gray area.

Yeah.

It's just important for patients to know that they can still carry some of the same risks as estradiol.

Okay.

Let's shift over to the natural counterbalance.

If estrogen is the builder, we need the maintainer to keep it in check, which is progesterone.

Right.

Progesterone is produced primarily by the corpus luteum and, if a pregnancy occurs, later by the placenta.

It's the hormone essential for preparing and maintaining the uterus for pregnancy.

Exactly.

And like estrogen, it acts on nuclear receptors.

Specifically, PRA receptors mediate inhibitory actions, while PRB receptors mediate stimulatory actions.

So physiologically, progesterone shifts that endometrium from a proliferative state into a secretory state.

Yes.

And if a pregnancy happens, progesterone levels stay high.

This sustained high level does two critical things to protect the fetus.

Okay.

What are they?

First, it suppresses the maternal immune system, preventing an immune attack on the foreign DNA of the fetus.

Wow.

I never thought of it like that.

And second, it suppresses the contraction of the uterine smooth muscle, preventing early delivery.

But there is a systemic consequence to suppressing smooth muscle, isn't there?

Oh, definitely.

It doesn't just isolate itself to the uterus.

It also suppresses gastrointestinal smooth muscle.

Which leads to prolonged GI transit time.

Yes.

Which is the exact mechanism behind why so many pregnant patients experience significant constipation.

Makes total sense when you break it down.

So therapeutically, we use progestins primarily to counteract estrogen in menopausal hormone therapy.

Right.

We also use them for dysfunctional uterine bleeding, omeria, and infertility treatments like IVF.

There's even a specific progestin hydroxyprogesterone caperate that's approved to prevent premature birth in specific high -risk populations.

But here is where the pharmacology feels contradictory again.

If progesterone is the very hormone that sustains pregnancy,

why does the textbook state that high -dose progestin therapy is contraindicated during early pregnancy?

I know.

It sounds totally contradictory, but it's all about the dosage.

Okay.

We are talking about high pharmacological doses introduced externally, not the body's natural endogenous baseline levels.

High -dose progestin therapy during the first four months of pregnancy has actually been shown to be teratogenic.

Teragenic, meaning it causes severe birth defects.

Yes, including limb reductions and congenital heart defects.

The baseline levels maintain the pregnancy, but overwhelming the developing fetus with pharmacological doses disrupts normal embryogenesis.

So we never administer high -dose progestins early on.

And when we look at the safety alerts, there is a very specific warning for combined therapy.

Right.

When you give estrogen plus progestin, you significantly increase the risks for DVT, stroke, pulmonary embolism, dementia in those over 65, and crucially, breast cancer.

Which is the perfect bridge into understanding the complexities of menopausal hormone therapy.

Yes.

Let's get into HT.

So when a patient reaches menopause, the production of ovarian estrogens decreases gradually,

and this loss triggers vasomotor symptoms.

Those intense hot flashes and night sweats.

Right, along with urogenital atrophy and rapid bone loss.

For decades, the standard medical response was to simply replace those hormones.

Up until the early 2000s, it was incredibly common to put almost all menopausal patients on hormone therapy, or HT.

It was viewed as like a protective fountain of youth.

But then came the publication of the Women's Health Initiative, or the WHI, and another study called HERS.

And the data released was shocking.

It showed that HT actually increased cardiovascular events, DVT, stroke, and for those taking combined estrogen and progestin, it increased breast cancer.

And the medical community panicked.

Prescriptions dropped by 80%.

Almost overnight.

But wait, when you look closely at the demographics of the women studied in the WHI trial, there is a massive flaw.

Oh, the demographic mismatch was staggering.

I mean, they were testing a drug meant to treat newly menopausal women, typically in their early 50s, on an entirely different population.

Right, the subjects in the original WHI data were much, much older.

Only like 3 .5 % of the participants were between 50 and 54 years old.

Exactly.

Many of the women were in their 70s and 80s, and they were taking high doses of hormones for prolonged periods.

The cardiovascular systems of 80 -year -olds are fundamentally different from those of 50 -year -olds.

So the spike in cardiovascular events wasn't necessarily a universal failure of the drugs?

No, it was a reflection of the study's design and the age of the participants.

That is wild.

Yeah.

When researchers later isolated the data and looked only at the newly menopausal patients, those aged 50 to 59, who were taking the therapy for less than 10 years, the clinical picture completely flipped.

Really?

Yeah.

For this younger cohort, the risks for venous thromboembolism were actually quite low.

And for patients taking estrogen -only therapy, there was no increase in coronary heart disease.

Wow.

In fact, for both regimens, the overall mortality rate was actually reduced by about five deaths per 1 ,000 women compared to the placebo group.

That is incredible.

A demographic misinterpretation fundamentally altered global medical practice for years.

It's a huge lesson in reading the fine print of clinical trials.

Absolutely.

So looking at the modern guidelines derived from the corrected data,

how do providers use HT today?

There are two main regimens, ET, which is estrogen -only, and EPT, which is estrogen plus progestin.

And the clinical rule is absolute, right?

Absolute.

EPT is mandatory for patients with an intact uterus.

You must include the progestin to protect against endometrial cancer.

Because you need the maintainer to stop the builder.

Exactly.

But if the patient has had a hysterectomy and no longer has a uterus, you use ET.

You never give progestin to a patient without a uterus because the progestin introduces unnecessary risks.

Particularly for breast cancer.

And the approved indications are very narrow.

First,

moderate to severe vasomotor symptoms, which are the hot flashes.

Second, vulvar and vaginal atrophy.

And for this indication, the text highly emphasizes using topical routes like vaginal creams, rings, or tablets.

To treat the local tissue while avoiding systemic absorption and all those associated risks.

Right.

And the third approved indication is the prevention of osteoporosis.

But this requires careful consideration.

Why is that?

Because preventing osteoporosis with hormones requires lifelong therapy.

The moment you stop ET,

bone mass drops rapidly up to 12%.

Oh wow.

And because lifelong systemic ET carries accumulating risks over decades,

alternative non -estrogen drugs are heavily preferred for long -term bone health.

That makes sense.

And just as important as knowing when to use it is knowing when absolutely not to.

Yes.

HT must never be used to prevent heart disease or Alzheimer dementia.

Despite older beliefs.

Right.

It confers no protection against these conditions and may actually accelerate the risks in older populations.

Okay.

So if a patient and provider decide to stop HT,

the discontinuation needs to be managed carefully.

Very carefully.

While there are no universally mandated guidelines, tapering is really common.

Like a dose taper.

Yeah.

A provider might use a dose taper, gradually reducing the daily milligrams of the medication, or a day taper, keeping the dose the same but skipping days between administrations.

And if the patient is on EPT, it's critical that only the estrogen dose is lowered initially,

Yes.

The progestin dose must remain the same to ensure the uterine lining continues to be protected as the estrogen withdraws.

Okay.

So while menopause is a major focus,

Chapter 64 also details pharmacological applications for premenopausal patients, specifically for female sexual interest arousal disorder, or FSIAD.

The text highlights two FDA -approved drugs for this condition.

The first is Phlebancerin, sold under the brand name Adi.

Adi, okay.

It's a daily oral pill that acts as a serotonin agonist and antagonist in the brain.

It alters neurotransmitter levels over time, meaning it actually takes weeks of daily use to see clinical effects.

But the adverse effects require serious nursing attention, right?

It can cause severe central nervous system depression and hypotension, which can lead to syncope or fainting.

Yes.

And there is a significant pharmacological mechanism behind this risk involving the liver.

Let's hear it.

So Phlebancerin is heavily metabolized by the CYP3A4 enzyme pathway in the liver.

Oh, the classic CYP3A4 interaction.

Exactly.

If a patient takes Phlebancerin alongside a CYP3A4 inhibitor, which could be another prescription drug or even something as common as grapefruit juice, the liver enzyme is blocked.

So it can't break down the Phlebancerin.

Right.

The drug rapidly builds up to toxic levels in the bloodstream, triggering that profound, dangerous drop in blood pressure.

Okay.

So the second approved drug operates entirely differently.

Bromelanotide or Valicy?

Yes.

Valicy is a subcutaneous injection used on an as -needed basis, typically 45 minutes before sexual activity.

It activates melanocortin receptors in the central nervous system.

So the administration method is different and so are the risks.

Definitely.

The most prominent adverse effect is nausea, which affects roughly 40 % of patients who use it.

40%.

That's really high.

It is.

It can also cause transient spikes in blood pressure and, in rare cases, focal hyperpigmentation.

Wait.

What is that?

It's a permanent darkening of the skin and gums.

Oh, wow.

Now, what's fascinating about these two drugs is the clinical gap in their approval.

The incidence of FSIAD spikes significantly after menopause, yet both fibanserin and bromelanotide are strictly FDA approved only for premenopausal patients.

Yeah.

And this is an excellent example of how pharmacology and clinical trials work in the real world.

How so?

Well, the original safety and efficacy trials for these drugs were exclusively focused on premenopausal populations.

As a nurse, you will frequently encounter these off -label boundaries.

Providers may prescribe a medication off -label based on clinical judgment, but you must understand what the drug was actually studied and approved for to accurately monitor for safety.

Exactly.

Let's bring it all home.

Let's take all of the cellular biology, these systemic mechanisms, and the clinical trial data and walk it straight onto the nursing floor.

Let's do it.

How do you apply this safely when caring for your patients?

Safe administration always begins with a thorough assessment.

Before initiating any estrogen or progestin therapy, patients require baseline breast and pelvic exams, blood pressure checks, and a definitive rule out of pregnancy.

And you're specifically screening for high -risk histories, right?

Anyone with a past DVT, estrogen -dependent tumors, or undiagnosed vaginal bleeding has an absolute contraindication.

Yes, absolute.

And when it comes to patient education, you are teaching them to recognize the mechanisms going wrong.

For the common, less dangerous side effects like nausea, teach patients to take their oral doses with food or at night before bed.

But crucially, you must instruct any patient on these therapies to report any recurrent or persistent vaginal bleeding immediately.

Right, because that is the primary warning sign that the builder has caused endometrial hyperplasia.

Leading to potential cancer, yes.

You also must emphasize the necessity of annual mammograms and clinical breast exams to monitor the systemic risks.

Okay, and what about self -administration, particularly with transdermal patches?

The instructions must be precise.

Teach the patient to apply the patch to a clean, dry area of the trunk or abdomen,

press it firmly for 10 seconds to ensure adhesion, and rotate the sites weekly to avoid skin irritation.

But the most important rule of the patch?

Yeah.

Never,

ever apply an estrogen patch to the breasts or the waistline.

Never.

Because telling a patient not to put a patch on their breast isn't just some random procedural rule.

It ties directly back to the breast cancer risk we discussed earlier.

Placing a transdermal estrogen delivery system directly over breast tissue creates a high localized concentration of a hormone known to stimulate tumor growth in that specific tissue.

It is exactly what we're trying to avoid, systemically concentrated locally.

See, when you understand the mechanism behind the rule, you become a much safer nurse.

You aren't just memorizing a list of do -nots, you are actively preventing pathology.

Absolutely.

Well, I want to leave you with a broader concept of Ponder that builds right on what we unpacked from the text today.

Oh, I like this.

What is it?

We saw how the Women's Health Initiative data caused a massive global medical panic, and how it was drastically misunderstood simply because the age of the subjects didn't match the age of the patients the drug was actually meant for.

The demographic mismatch.

Exactly.

It really makes you wonder how many other drugs in your pharmacology textbook currently have a bad reputation, or even a black box warning,

simply because the original clinical trials didn't perfectly match the modern, real -world patient population.

That is a fascinating thought.

Right.

It is a stark reminder that as the nurse reading a chart or a study, you must always look at who was actually studied, not just the headline.

It really is a critical perspective to carry forward.

Questioning the data and understanding the demographics will serve you well in any clinical specialty.

Thank you for joining us on this deep dive into Chapter 64.

From everyone here on the Last Minute Lecture Team, we are wishing you the absolute best of luck on your pharmacology exam.

You've got this.